You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
|---|---|
| Published in |
Clinical Cancer Research, August 2017
|
| DOI | 10.1158/1078-0432.ccr-16-2818 |
| Pubmed ID | |
| Authors |
Myron S. Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M. Linton, Nina Wagner-Johnston, Randy D. Gascoyne, Graham W. Slack, Pierre Brousset, David A. Eberhard, Francisco J. Hernandez-Ilizaliturri, Gilles Salles, Thomas E. Witzig, Pier Luigi Zinzani, George W. Wright, Louis M. Staudt, Yandan Yang, P. Mickey Williams, Chih-Jian Lih, Jacqueline Russo, Anjan Thakurta, Patrick Hagner, Pierre Fustier, Dale Song, Ian D. Lewis |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 25% |
| United Kingdom | 1 | 8% |
| Mexico | 1 | 8% |
| Unknown | 7 | 58% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 75% |
| Scientists | 2 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 128 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 23% |
| Other | 17 | 13% |
| Student > Bachelor | 9 | 7% |
| Student > Ph. D. Student | 8 | 6% |
| Student > Doctoral Student | 6 | 5% |
| Other | 22 | 17% |
| Unknown | 37 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 41% |
| Biochemistry, Genetics and Molecular Biology | 9 | 7% |
| Nursing and Health Professions | 7 | 5% |
| Agricultural and Biological Sciences | 4 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Other | 10 | 8% |
| Unknown | 41 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2023.
All research outputs
#2,060,766
of 26,017,215 outputs
Outputs from Clinical Cancer Research
#1,618
of 13,415 outputs
Outputs of similar age
#38,438
of 331,208 outputs
Outputs of similar age from Clinical Cancer Research
#49
of 254 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,415 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.9. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,208 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 254 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.